Assessment of Changes in Both Weight and Frequency of Use of Medications for the Treatment of Gastrointestinal Symptoms Among Clozapine-Treated Patients

REFERENCES

• Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Col-laborative Study Group: Clozapine for the treatment-resistant schizophrenic: Double-blind comparison with chlorpro-mazine. Arch Gen Psychiatry 1988; 45:789–796
   PubMed Web of Science ®Google Scholar
• Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329:162–167
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Frankenburg FR: Clozapine. A novel antip-sychotic agent. N Engl J Med 1991; 324:746–754
   PubMed Web of Science ®Google Scholar
• Clozaril product information. In: Physicians Desk Refer-ence —PDR, 49th ed. Montvale, N.J.: Medical Economics Data Production; 1995:2149–2153
   Google Scholar
• Bo-Linn OW: Obesity, anorexia nervosa, bulimia and other eating disorders. In: Scharschmidt BF, Feldman M, eds. Gas-trointestinal Diseases: Pathophysiology, Diagnosis and Man-agement. Philadelphia: Saunders, 1993:2109–2136
   Google Scholar
• McCarthy RH, Terkelson KG: Esophageal dysfunction in two patients after clozapine treatment (letter). J Clin Psychophar-macol 1994; 14:281–283
   PubMed Web of Science ®Google Scholar
• Dinan TG, Yatham LN, Barry S: Serotonin supersensitivity: The pathophysiologic basis of non-ulcer dyspepsia? Scand J Gastroenterol 1990; 25:541–544
   PubMed Web of Science ®Google Scholar
• Patel AR, Snape WJ Jr: Prokinetic agents and antiemetics. In: Wolfe MM, ed. Gastrointestinal Pharmacotherapy. Phila-delphia: Saunders; 1993:1–24
   Google Scholar
• Scott DR, Hersey Si, Prinz C, Sachs G: Actions of antiulcer drugs (letter). Science 1993; 262:1453–1455
   Google Scholar
• Mezey E, Palkovits M: Localization of targets for anti-ulcer drugs in cells of the immune system. Science 1992; 258:1662–1665
   PubMed Web of Science ®Google Scholar
• Shields LI, Files JA, Doll DC, Greenburg BR: Ranitidine and agranulocytosis (letter). Ann Intern Med 1986; 104:128
   PubMed Web of Science ®Google Scholar
• Lane GP, Speed B: Agranulocytosis after ranitidine admini-stration. Med J of Austral. 1989; 150:595–596.
   Google Scholar
• Glaxo Pharmaceuticals: Zantac product information. In: Phy-sicians Desk Reference—PDR, 48th ed. Montvale, NJ: Medi-cal Economics Data Production; 1994:1018–1021
   Google Scholar
• Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M: Clozapine-induced-weight gain: Prevalence and clinical relevance. Am J Psychiatry 1992; 149:68–72
   PubMed Web of Science ®Google Scholar
• Cohen S, Chiles J, Macnaughton A: Weight gain associated with clozapine. Am J Psychiatry 1990; 147:503–504
   PubMed Web of Science ®Google Scholar
• Umbricht, DSG, Pollack S, Kane, JM: Clozapine and weight gain. J Clin Psychiatry 1994; 55(9, Suppl B):157–160
   Google Scholar
• Doss FW: The effect of antipsychotic drugs on body weight: A retrospective review. J Clin Psychiatry 1979; 40:528–530
   PubMed Web of Science ®Google Scholar
• Holden JMC, Holden UP: Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1970; 9:551–561
   Google Scholar
• Klett CJ, Caffey EM Jr: Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 1960; 2:102–108
   PubMedGoogle Scholar
• Amdisen, A: Drug-produced obesity: Experiences with chlor-promazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11:182–189
   PubMedGoogle Scholar
• Johnson DAW, Breen M: Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 1979; 59:525–528
   PubMedGoogle Scholar
• Marriott P, Pansa M, Hiep A: Depot fluphenazine mainte-nance treatment and associated weight changes. Compr Psy-chiatry 1981; 22:320–325
   Google Scholar
• Brady KT: Weight gain associated with psychotropic drugs. South Med J 1989; 82:611–617
   PubMed Web of Science ®Google Scholar
• Gardos G, Cole JO: Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977; 134:302–304
   Google Scholar
• Davis JM, Janicak PG, Preskorn S, Ayd FJ Jr: Advances in the pharmacotherapy of psychotic disorders (Update). In: Janicak PG, et al., ed. Principles, and Practice of Psychophar-macotherapy. Baltimore: Williams and Wilkins; 1994: 12
   Google Scholar
• Hemphill RE, Pascoe FD, Zabow T: An investigation of clozapine in the treatment of acute and chronic schizophrenia and gross behaviour disorders. S Mr Med J 1975; 49:2121–2125
   Google Scholar
• Nair NPV, Zicherman V, Schwartz G: Dopamine in schizo-phrenia: A reappraisal in the light of clinical studies with clozapine. Can Psychiatr Assoc J 1977; 22:285–293
   PubMedGoogle Scholar
• Povlsen UJ, Noring U, Fog R, Gerlach J: Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71:176–185
   PubMed Web of Science ®Google Scholar
• Lamberti JS, Bellnier R, Schwarzkopf SB: Weight gain among schizophrenic patients treated with clozapine. Am J Psychia-try 1992; 149:689–690
   PubMed Web of Science ®Google Scholar
• Wiebe, EJ: Weight gain with clozapine treatment (letter). Can J Psychiatry 1993; 38(1):70
   Google Scholar
• Dufresne RL, Valentino D, Kass DJ: Thioridazine improves affective symptoms in schizophrenic patients. Psychopharma-col Bull 1993; 29:249–255
   PubMedGoogle Scholar
• Morley JE: Appetite regulation: The role of peptides and hor-mones. J Endocrinol Invest 1989; 12:135–147
   PubMed Web of Science ®Google Scholar
• Bray GA: Genetic and hypothalamic mechanisms for obe-sity—finding the needle in the haystack. Am J Clin Nutr 1989; 50:891–902
   PubMed Web of Science ®Google Scholar
• Goldbloom DS, Garfinkel PE: The serotonin hypothesis of bulimia nervosa: Theory and evidence. Can J Psychiatry 1990; 35:741–744.
   Google Scholar
• Hayes G, Gibler B: Clozapine-induced constipation. Am J Psychiatry 1995; 152:298
   PubMed Web of Science ®Google Scholar